Novel transcript, antisense to GFRA1 (ENSG00000299238)

This gene encodes a presumed non-coding natural antisense transcript complementary to the GFRA1 locus. Natural antisense transcripts (NATs) are a class of long non-coding RNAs that overlap protein-coding genes in antisense orientation and can modulate the expression or stability of their sense partners by various mechanisms, including formation of double-stranded RNA duplexes and masking of microRNA binding sites[1]. For example, well-studied NATs such as BACE1-AS can increase or decrease the stability and expression of the sense mRNA and are often regulated under stress or disease conditions[1]. The specific biological function or disease relevance of "novel transcript, antisense to GFRA1" (ENSG00000299238) has not been experimentally characterized or demonstrated in the published literature or major gene databases as of September 2025. It is NOT considered a canonical therapeutic target such as a receptor, enzyme, transporter, or transcription factor[1][3]. Key clarifications: - The canonical therapeutic target here is *Glial cell line-derived neurotrophic factor receptor alpha 1* (GFRA1), a genuine receptor protein-coding gene with significant roles in neurodevelopment and disease[3]. The antisense transcript in question does not encode a receptor or protein, and is only annotated as a novel, regulatory non-coding RNA. - *Is_incorrect* is marked true because this entry is not recognized as a standalone drug target, receptor, or disease biomarker, and lacks established biological or biomedical relevance. If you intended the *protein-coding* GFRA1 receptor, see "Glial cell line-derived neurotrophic factor receptor alpha 1 (GFRA1)" for relevant target annotations[3].

Other names

antisense to GFRA1GFRA1-ASENSG00000299238